Werewolf Therapeutics, Inc. Financials

No, Werewolf Therapeutics, Inc. (HOWL) reported a net income of -$70.5M in fiscal year 2024.

Werewolf Therapeutics, Inc. (HOWL) reported diluted earnings per share of $-1.63 for fiscal year 2024. This represents a -55.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Werewolf Therapeutics, Inc. (HOWL) had EBITDA of -$71.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2024, Werewolf Therapeutics, Inc. (HOWL) had $111.0M in cash and equivalents against $32.1M in long-term debt.

Werewolf Therapeutics, Inc. (HOWL) generated -$56.4M in free cash flow during fiscal year 2024. This represents a -69.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Werewolf Therapeutics, Inc. (HOWL) generated -$56.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Werewolf Therapeutics, Inc. (HOWL) had $126.9M in total assets as of fiscal year 2024, including both current and long-term assets.

Werewolf Therapeutics, Inc. (HOWL) invested $254K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Werewolf Therapeutics, Inc. (HOWL) invested $56.4M in research and development during fiscal year 2024.

Werewolf Therapeutics, Inc. (HOWL) had 45M shares outstanding as of fiscal year 2024.

Werewolf Therapeutics, Inc. (HOWL) had a current ratio of 7.45 as of fiscal year 2024, which is generally considered healthy.

Werewolf Therapeutics, Inc. (HOWL) had a debt-to-equity ratio of 0.44 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Werewolf Therapeutics, Inc. (HOWL) had a return on assets of -55.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Werewolf Therapeutics, Inc. (HOWL) had $111.0M in cash against an annual operating cash burn of $56.2M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Werewolf Therapeutics, Inc. (HOWL) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Werewolf Therapeutics, Inc. (HOWL) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Werewolf Therapeutics, Inc. (HOWL) has an interest coverage ratio of -22.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.